Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... provider of scientific, technical and medical information products and ... in Reproductive BioMedicine Online on ... abnormal chromosomal composition can be identified by the rate ... the risk of genetic abnormality without a biopsy. In ... retrospective study, using their predictive model to assess the ...
(Date:5/17/2013)... PALO ALTO, Calif. , May 17, 2013 ... that it has achieved 50% enrollment of the ... trial to evaluate the safety and preliminary efficacy ... Progenitor Cells) therapy for Knee Osteoarthritis (KOA). To ... Effect (SAE) reported. The Phase I ...
(Date:5/17/2013)... 2013 Men’s skin is biologically different than ... ) and has been known to react more aggressively when ... be far from puberty, other acne causing factors like P.acnes ... and threatening skin with unsightly acne scars. Adult acne treatment, ... Health on how to reduce and prevent acne scarring. ...
(Date:5/17/2013)... IAC Industries wants to share with you the success ... set up and furnish a research lab knowing that the ... year’s time. How does a company make choices in lab ... is efficient and cost-effective? , The solution was the ... planners at DisperSol determined that the concept of modular lab ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Adult Acne Treatment, Probiotic Action Shares New Insight on Why Men’s Skin Scars from Acne and How to Prevent It 2New Downloadable Success Story: “How To Outfit a Dynamic Lab in Flux” 2
... Nile Therapeutics,Inc. (OTC Bulletin Board: NILT.OB), a ... today announced the,appointment of Gregory W. Schafer to ... audit committee. Mr. Schafer is a seasoned biotechnology ... finance and operations., "We are delighted to ...
... Lentigen Corporation today announced,the appointment of Tim Ravenscroft ... chairman, commented, "The board of Lentigen,is delighted that ... are about to enter,clinical trials for our first ... particularly strong background and global leadership in,healthcare products ...
... Arno Therapeutics, Inc., a,privately held drug development ... license agreements with The Ohio State University,("OSU") for ... therapies for cancer., Pursuant to the license ... for the treatment of cancer, including OSU-03012 (NSC,D728209) ...
Cached Biology Technology:Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 2Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors 3Lentigen Appoints Tim Ravenscroft as Chief Executive Officer 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 3
(Date:5/16/2013)... creature with ,scissor hand-like, claws in fossil records and ... star. , The 505 million year old fossil ... is a distant ancestor of lobsters and scorpions, was ... role as Edward Scissorhands - a movie about an ... scissors for hands. , Kooteninchela deppi ...
(Date:5/16/2013)... of genome-wide analysis (GWA), where the entirety of an ... mutations or variants which can cause health problems is ... it can also pose major ethical problems if used ... Human Genetics (ESHG) published on line today (16 May ... ., Many services based on whole genome and on ...
(Date:5/16/2013)... Most of us don,t ponder our pulses outside of the ... tool to monitor heart health. , Zhenan Bao, a professor ... thinner than a dollar bill and no wider than a ... bandage on the wrist, is sensitive enough to help doctors ... one day be used to continuously track heart health and ...
Breaking Biology News(10 mins):Actor Johnny Depp immortalized in ancient fossil find 2European Society of Human Genetics urges caution over use of new genetic sequencing techniques 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3
... the International Society for Computational Biology (ISCB) are delighted ... the journal Bioinformatics will once again become ... Bioinformatics and the ISCB have always ... the new official partnership. ISCB members enjoy a substantial ...
... Screening for mutations in a gene that helps ... predict which children are at higher risk for side ... rejection, according to new research. Published online Feb. ... Pharmacology and Therapeutics , the study suggests this genetic ...
... is often thought of as harmful yet few know ... further research the role of bacteria in water treatment, ... institutions across three continents. Researchers will study the mechanisms ... the microbial will enable us to come up with ...
Cached Biology News:Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplants 2Gene mutation increases drug toxicity, rejection risk in pediatric kidney transplants 3NTU seals global partnerships on environmental sciences R&D 2
Phospho-C/EBPbeta (Thr235) Antibody...
Rac1/2/3 (L129) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
... UbcH7 interacts with the ... c-Cbl RING domain. Evidence suggests ... in both the degradation of ... of certain N-a -acetylated proteins ...
Goat polyclonal to Sarcosine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Full length protein: Sarcosine Oxidase (microbial). Entrez Gene ID: 51268 Swiss Protein ID: ...
Biology Products: